Go Pro

Francois Brisebois Analyst Performance

Analyst at Lifesci Capital

Francois Brisebois is a stock analyst at Lifesci Capital focused in the healthcare sector, covering 22 publicly traded companies. Over the past year, Francois Brisebois has issued 10 stock ratings, including and buy recommendations. While full access to Francois Brisebois' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Francois Brisebois' coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
32 Last 8 Years
Buy Recommendations
93.33% 28 Buy Ratings
Companies Covered
22 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy93.3%28 ratings
Hold6.7%2 ratings
Sell0.0%0 ratings

Out of 30 total stock ratings issued by Francois Brisebois at Lifesci Capital, the majority (93.3%) have been Buy recommendations, followed by 6.7% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
95.5% of companies on NASDAQ
21 companies
NYSE
4.5% of companies on NYSE
1 company

Francois Brisebois, an analyst at Lifesci Capital, currently covers 22 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
20 companies
90.9%
Miscellaneous
1 company
4.5%
Finance
1 company
4.5%

Francois Brisebois of Lifesci Capital specializes in stock coverage within the Healthcare sector, with additional focus on and Finance companies.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
11 companies
50.0%
PHARMACEUTICALS
8 companies
36.4%
Miscellaneous
1 company
4.5%
LIFE SCIENCES TOOLS & SERVICES
1 company
4.5%
CAPITAL MARKETS
1 company
4.5%

Francois Brisebois' Ratings History at Lifesci Capital

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Apnimed, Inc. stock logo
APMD
Apnimed
8/25/2026Initiated Coverage$28.27$50.00Outperform
MediWound Ltd. stock logo
MDWD
MediWound
8/14/2026Reiterated Rating$13.67$30.00Outperform
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
8/12/2026Boost Price Target$69.46$100.00Outperform
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
8/5/2026Reiterated Rating$13.58Outperform
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
7/7/2026Reiterated Rating$12.93$20.00Outperform
MediWound Ltd. stock logo
MDWD
MediWound
5/27/2026Reiterated Rating$14.33$32.00Outperform
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
4/6/2026Boost Price Target$13.15$23.00Outperform
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
2/25/2026Boost Price Target$75.07$105.00Outperform
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
2/12/2026Set Price Target$6.31$15.00
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
9/8/2025Boost Price Target$5.42$8.00Outperform
Savara Inc. stock logo
SVRA
Savara
8/15/2025Boost Price Target$3.06$6.00Outperform
Sensei Biotherapeutics, Inc. stock logo
FTH
Sensei Biotherapeutics
3/28/2025Boost Price Target$8.62$80.00Outperform
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
3/5/2025Initiated Coverage$5.07$16.00Outperform
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
1/29/2025Upgrade$0.74$4.00Outperform
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
1/22/2025Boost Price Target$47.34$72.00Outperform